NCT06764329Phase 1/2Enrolling by invitation
The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia.
The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia: a Randomized, Double-Blind, Placebo Control Trial
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Enrolling by invitation
- Declared phase
- Phase 1/2
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
- Participants (registry)
- 70
- Start
- December 2024
- Primary completion
- June 2025
- Study completion
- August 2025
- Last registry update
- January 2025
- Countries
- Pakistan
Conditions studied: Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Interventions: Mesenchymal Stem Cells, 0.9 % saline
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.